Neurology
RCT: Efficacy and safety of fenfluramine for the treatment of seizures associated With Lennox-Gastaut Syndrome.
16 May, 2022 | 01:29h | UTCCommentaries:
Fenfluramine Found Effective for Treatment of Lennox-Gastaut Syndrome Seizures – NeurologyToday
Fenfluramine Seems Effective for Lennox-Gastaut Syndrome – HealthDay
Commentary on Twitter
In this randomized clinical trial, fenfluramine was a safe and effective treatment option for patients with Lennox-Gastaut syndrome. https://t.co/Ukopx9cV9r @Zogenix pic.twitter.com/dRetoOZSiB
— JAMA Neurology (@JAMANeuro) May 2, 2022
Review: Radiological assessment of chronic subdural hematomas.
16 May, 2022 | 01:17h | UTCRadiological Assessment of Chronic Subdural Hematomas – Korean Journal of Neurotrauma
Risk factors associated with Alzheimer disease and related dementias by sex and race and ethnicity in the US.
13 May, 2022 | 10:55h | UTCRisk Factors Associated With Alzheimer Disease and Related Dementias by Sex and Race and Ethnicity in the US – JAMA Neurology (free for a limited period)
Commentaries:
Alzheimer’s and Dementia Linked to Eight Modifiable Risk Factors – Psychiatric News Alert
The 3 Midlife Factors That Raise Your Odds for Alzheimer’s – HealthDay
M-A: Comparative impact of pharmacological therapies on cluster headache management.
12 May, 2022 | 08:01h | UTC
Systematic Review: Prevention of peripheral distal polyneuropathy in patients with diabetes.
12 May, 2022 | 07:58h | UTC
Rapidly progressive dementias — etiologies, diagnosis and management.
10 May, 2022 | 10:59h | UTCRapidly progressive dementias — aetiologies, diagnosis and management – Nature Reviews Neurology (if the link is paywalled, try this one in PMC)
Review: Assessment and management of cognitive function in patients with prostate cancer treated with second-generation androgen receptor pathway inhibitors.
10 May, 2022 | 10:32h | UTC
RCT: Terminal complement inhibitor Ravulizumab in generalized myasthenia gravis.
9 May, 2022 | 01:27h | UTCTerminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis – NEJM Evidence
Commentary on Twitter
In this RCT, Ravulizumab provided rapid and efficacious treatment of adult patients with anti-AChR antibody-positive generalized myasthenia gravis (gMG), as determined by both patient- and clinician-rated outcomes, with few adverse events. https://t.co/9mlCOULiJR#NeuroTwitter pic.twitter.com/ZljrTs282f
— NEJM Evidence (@NEJMEvidence) May 3, 2022
Systematic Review: Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis.
6 May, 2022 | 10:47h | UTCSummary: Cannabis and cannabinoids for people with multiple sclerosis – Cochrane Library
Commentary on Twitter
💚A UK survey found that 1 in 5 people with #MS reported they used #Cannabis to manage symptoms.
🤔 Does it work? Are there harms?
📚 Cochrane systematic review looks at 25 RCTs ➡️ https://t.co/HCt6Cx3suo#MedicalMarijuana #MultipleSclerosis pic.twitter.com/wjDTXXEciM— The Cochrane Library (@CochraneLibrary) May 5, 2022
2022 HRS expert consensus statement on evaluation and management of arrhythmic risk in neuromuscular disorders.
5 May, 2022 | 10:22h | UTC
Management of patients presenting to the emergency department with sudden onset severe headache: systematic review of diagnostic accuracy studies.
5 May, 2022 | 10:08h | UTC
Current Guidelines on management of amaurosis fugax and transient ischemic attacks.
5 May, 2022 | 09:50h | UTC
M-A: Efficacy and safety of Selumetinib in pediatric patients with Neurofibromatosis Type 1.
5 May, 2022 | 09:41h | UTCEfficacy and Safety of Selumetinib in Pediatric Patients With Neurofibromatosis Type 1: A Systematic Review and Meta-analysis – Neurology (link to abstract – $ for full-text)
Commentary on Twitter
A study via @GreenJournal reported that #selumetinib is a safe and effective treatment for pediatric patients with symptomatic, inoperable plexiform neurofibromas, but further studies are needed to confirm long-term outcomes. https://t.co/sRVaNFPKwV#NeuroTwitter pic.twitter.com/hYJNpN1EoU
— Neurology Today (@NeurologyToday) March 11, 2022
Perspective: Less pharmacotherapy is more in delirium.
3 May, 2022 | 10:56h | UTCLess pharmacotherapy is more in delirium – Intensive Care Medicine (if the link is paywalled, try this one)
Related:
Effectiveness of Bundle Interventions on ICU Delirium: A Meta-Analysis – Critical Care Medicine
Commentary on Twitter
⬇️ 💉Less medications (& ⬆️ awareness of behavioural interventions) is more in #delirium, common, challenging/costly (but often preventable) in #ICU. Despite lacking evidence, medications widely used.
Prevent/minimize addressing suspected contributors!
📎 https://t.co/fYWAsIcuiZ pic.twitter.com/DyC3agSP7w— Intensive Care Medicine (@yourICM) April 30, 2022
Contemporary antiplatelet therapy for secondary stroke prevention: a narrative review of current literature and guidelines.
3 May, 2022 | 10:26h | UTC
M-A: Comparative safety and efficacy of cognitive enhancers for Alzheimer’s dementia.
1 May, 2022 | 23:10h | UTC
Systematic Review: Antiepileptic drugs for the primary and secondary prevention of seizures after stroke.
29 Apr, 2022 | 10:45h | UTC
Systematic Review: Diagnostic test accuracy of remote, multidomain cognitive assessment (telephone and video call) for dementia.
29 Apr, 2022 | 11:09h | UTCSummary: How accurate are remote, virtual assessments at diagnosing dementia? – Cochrane Library
Systematic Review: Psychological treatments for depression and anxiety in dementia and mild cognitive impairment.
28 Apr, 2022 | 10:33h | UTC
NICE Guideline: Epilepsies in children, young people and adults.
27 Apr, 2022 | 08:14h | UTCEpilepsies in children, young people and adults – National Institute for Health and Care Excellence
Cohort Study: Incidence of Guillain-Barré syndrome after Covid-19 vaccination in the vaccine safety datalink.
27 Apr, 2022 | 08:03h | UTC
Commentary on Twitter
This cohort study of #COVID19 vaccine safety surveillance in the US Vaccine Safety Datalink found a small elevated risk of Guillain-Barré syndrome after Janssen/J&J vaccine but not after mRNA COVID-19 vaccines. @KPDOR https://t.co/TTya5BDqeV
— JAMA Network Open (@JAMANetworkOpen) April 26, 2022
Brief Review: EEG monitoring after cardiac arrest.
27 Apr, 2022 | 07:55h | UTCEEG monitoring after cardiac arrest – Intensive Care Medicine
Commentary on Twitter
EEG after cardiac arrest:
🧠 to assess severity/provide prognostic info: background voltage, continuity, reactivity; time course post CA
⚡️ EEG to detect & treat epileptiform activity/monitor effectiveness of antiepileptics
📼 continuous recording#FOAMcchttps://t.co/2ZJGHkNgv6 pic.twitter.com/TmfxXlAAom— Intensive Care Medicine (@yourICM) April 26, 2022
Longitudinal associations of mental disorders with dementia: 30-year analysis of 1.7 million New Zealand citizens.
27 Apr, 2022 | 07:51h | UTCNews Release: Mental disorders may increase risk for subsequent dementia – University of Michigan
Commentary: Mental Disorders Tied to Subsequent Dementia Onset – HealthDay
Commentary on Twitter
In this longitudinal population-register study of 1.7 million New Zealand citizens, individuals with #mentalhealth disorders had elevated risk for #dementia when followed up years later. https://t.co/kkOUOnHEXE
— JAMA Psychiatry (@JAMAPsych) April 15, 2022
Brain death: a clinical overview.
27 Apr, 2022 | 07:48h | UTCBrain death: a clinical overview – Journal of Intensive Care
Commentary on Twitter
A Review published in the Journal of Intensive Care discusses the philosophy and history of brain death, its clinical determination, special considerations and the main clinical components of the brain death exam. https://t.co/2syaHQVftO
— BMC (@BioMedCentral) March 22, 2022
A practical guide to the treatment of Dravet Syndrome with anti-seizure medication.
27 Apr, 2022 | 01:32h | UTCA Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication – CNS Drugs